X4 Pharmaceuticals, Inc — Director's Dealing 2019

Mar 15, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2019-03-13

Reporting Person: Ragan Paula (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-13	Common Stock	A	181366	—	Acquired	181366	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-13	Stock Option (right to buy)	$6.84	A	100729	Acquired	2026-01-18	Common Stock (100729)	Direct
2019-03-13	Stock Option (right to buy)	$6.84	A	65430	Acquired	2027-01-23	Common Stock (65430)	Direct
2019-03-13	Stock Option (right to buy)	$7.08	A	80160	Acquired	2028-01-30	Common Stock (80160)	Direct

Footnotes

F1: Received in exchange for 1,870,000 shares of common stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") and 38,451 shares of Series Seed preferred stock of X4 in connection with the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 (the "Merger") on March 13, 2019.

F2: Fully vested.

F3: Reflects the Reporting Person's stock option to acquire 1,059,935 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger.

F4: Twenty-five percent (25%) of the shares subject to the option vested on January 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F5: Reflects the Reporting Person's stock option to acquire 688,500 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger.

F6: Twenty-five percent (25%) of the shares subject to the option vested on January 31, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F7: Reflects the Reporting Person's stock option to acquire 843,496 shares of X4 common stock for $0.67 per share that was assumed by the Issuer in the Merger.